Canadian Pharmacists Journal最新文献_第10页

Barriers to pharmacy practice change 药房实践的障碍改变了

IF 1.5

Canadian Pharmacists Journal Pub Date : 2016-10-06 DOI: 10.1177/1715163516672832

Meagen M Rosenthal, Z. Austin, R. Tsuyuki

{"title":"Barriers to pharmacy practice change","authors":"Meagen M Rosenthal, Z. Austin, R. Tsuyuki","doi":"10.1177/1715163516672832","DOIUrl":"https://doi.org/10.1177/1715163516672832","url":null,"abstract":"The practice of pharmacy has seen major changes in the past decade. Today, pharmacists from coast to coast can extend prescriptions and make therapeutic substitutions. Many pharmacists can also provide influenza vaccinations and in some cases initiate drug therapies (i.e., prescribe). However, it has also been well established that the integration of many of these services by pharmacists into practice has been slow and incomplete. As pharmacy regulatory and advocacy groups continue to push for pharmacists’ larger role within the health care system, these efforts are hampered by the lack of widespread adoption and integration of these services within practice. Therefore, we need to more carefully consider why pharmacy practice change has been so challenging. In 2010, we wrote a commentary titled “Are Pharmacists the Ultimate Barrier to Pharmacy Practice Change?” In that article, we suggested that pharmacists’ personality traits, including lack of confidence, fear of new responsibility, paralysis in the face of ambiguity, need for approval and risk aversion, were the heretofore unspoken barriers to practice change. Using this commentary as a starting point, the purpose of this editorial is to discuss the issue of whether it is our innate personality traits (“nature”) or our professional pharmacy culture (“nurture”) that holds us back.","PeriodicalId":46612,"journal":{"name":"Canadian Pharmacists Journal","volume":"149 1","pages":"317 - 319"},"PeriodicalIF":1.5,"publicationDate":"2016-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1715163516672832","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65467457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 22

Evaluation of a continuous quality improvement program in anticoagulant therapy 抗凝治疗持续质量改进方案的评价

IF 1.5

Canadian Pharmacists Journal Pub Date : 2016-10-06 DOI: 10.1177/1715163516671334

Ariane Cantin, Alexandre Lahaie, Bojan Odobasic, Marie-Philip Tremblay, Dana Wazzan, Stéphanie Caron, C. Leblanc, J. Martineau, L. Lalonde

{"title":"Evaluation of a continuous quality improvement program in anticoagulant therapy","authors":"Ariane Cantin, Alexandre Lahaie, Bojan Odobasic, Marie-Philip Tremblay, Dana Wazzan, Stéphanie Caron, C. Leblanc, J. Martineau, L. Lalonde","doi":"10.1177/1715163516671334","DOIUrl":"https://doi.org/10.1177/1715163516671334","url":null,"abstract":"Background: The ACO Program (Programme ACO), a continuous quality improvement program (CQIP) in anticoagulation therapy, was offered in community pharmacies as a pilot project. Objective: To evaluate the participants’ appreciation for the various activities of the program. Methods: Participants had access to training activities, including an audit with feedback, online training activities (OTA), clinical tools and support from facilitators. Cognitive behavioural learning determinants were evaluated before and 5 months after the beginning of the program. Participants’ satisfaction and perception were documented via online questionnaires and a semistructured interview. Results: Of the 52 pharmacists in the ACO Program, 47 participated in this evaluation. Seventy-seven percent of the participants completed at least 1 OTA and 6% published on the forum. The feeling of personal effectiveness rose from 8.01 (7.67-8.35) to 8.62 (8.24-8.99). The audit and feedback, as well as the high-quality OTA and their lecturers, were the most appreciated elements. Discussion: There was a high OTA participation rate. The facilitators seemed to play a key role in the CQIP. The low level of participation in the forum reflects the known phenomenon of social loafing. Technical difficulties affecting the platform and data collection for the audit with feedback constituted limitations. Conclusion: The CQIP in anticoagulation therapy is appreciated by community pharmacists and is associated with an improved feeling of personal effectiveness.","PeriodicalId":46612,"journal":{"name":"Canadian Pharmacists Journal","volume":"149 1","pages":"352 - 361"},"PeriodicalIF":1.5,"publicationDate":"2016-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1715163516671334","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65467306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Fitting naloxone into community pharmacy practice 纳洛酮在社区药学实践中的应用

IF 1.5

Canadian Pharmacists Journal Pub Date : 2016-10-06 DOI: 10.1177/1715163516671968

K. Grindrod, M. Beazely

引用次数: 2

Pay-for-performance remuneration for pharmacist prescribers’ management of hypertension 处方药师管理高血压的绩效薪酬

IF 1.5

Canadian Pharmacists Journal Pub Date : 2016-10-03 DOI: 10.1177/1715163516671745

S. Houle, T. Charrois, F. McAlister, M. Kolber, Meagen M Rosenthal, R. Lewanczuk, N. Campbell, R. Tsuyuki

{"title":"Pay-for-performance remuneration for pharmacist prescribers’ management of hypertension","authors":"S. Houle, T. Charrois, F. McAlister, M. Kolber, Meagen M Rosenthal, R. Lewanczuk, N. Campbell, R. Tsuyuki","doi":"10.1177/1715163516671745","DOIUrl":"https://doi.org/10.1177/1715163516671745","url":null,"abstract":"Background: To be sustainable, pharmacists providing direct patient care must receive appropriate payment for these services. This prespecified substudy of the RxACTION trial (a randomized trial of pharmacist prescribing vs usual care in patients with above-target blood pressure [BP]) aimed to determine if BP reduction achieved differed between patients whose pharmacist was paid by pay-for-performance (P4P) vs fee-for-service (FFS). Methods: Within RxACTION, patients with elevated BP assigned to the pharmacist prescribing group were further randomized to P4P or FFS payment for the pharmacist. In FFS, pharmacists received $150 for the initial visit and $75 for follow-up visits. P4P included FFS payments plus incentives of $125 and $250 for each patient who reached 50% and 100% of the BP target, respectively. The primary outcome was difference in change in systolic BP between P4P and FFS groups. Results: A total of 89 patients were randomized to P4P and 92 to the FFS group. Patients’ average (SD) age was 63.0 (13.2) years, 49% were male and 76% were on antihypertensive drug therapy at baseline, taking a median of 2 (interquartile range = 1) medications. Mean systolic BP reductions in the P4P and FFS groups were 19.7 (SD = 18.4) vs 17.0 (SD = 16.4) mmHg, respectively (p = 0.47 for the comparison of deltas and p = 0.29 after multivariate adjustment). Conclusions: This trial of pharmacist prescribing found substantial reductions in systolic BP among poorly controlled hypertensive individuals but with no appreciable difference when pharmacists were paid by P4P vs FFS.","PeriodicalId":46612,"journal":{"name":"Canadian Pharmacists Journal","volume":"149 1","pages":"345 - 351"},"PeriodicalIF":1.5,"publicationDate":"2016-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1715163516671745","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65467371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 10

Tighter regulations needed for over-the-counter codeine in Canada 加拿大需要加强对非处方可待因的监管

IF 1.5

Canadian Pharmacists Journal Pub Date : 2016-08-10 DOI: 10.1177/1715163516660572

J. Mackinnon

引用次数: 12

Uptake of the MedsCheck annual medication review service in Ontario community pharmacies between 2007 and 2013 2007年至2013年安大略省社区药房MedsCheck年度药物审查服务的使用情况

IF 1.5

Canadian Pharmacists Journal Pub Date : 2016-08-09 DOI: 10.1177/1715163516662670

L. Dolovich, Giulia P. Consiglio, L. Mackeigan, L. Abrahamyan, P. Pechlivanoglou, V. Rac, N. Pojskic, Elizabeth A. Bojarski, J. Su, M. Krahn, S. Cadarette

{"title":"Uptake of the MedsCheck annual medication review service in Ontario community pharmacies between 2007 and 2013","authors":"L. Dolovich, Giulia P. Consiglio, L. Mackeigan, L. Abrahamyan, P. Pechlivanoglou, V. Rac, N. Pojskic, Elizabeth A. Bojarski, J. Su, M. Krahn, S. Cadarette","doi":"10.1177/1715163516662670","DOIUrl":"https://doi.org/10.1177/1715163516662670","url":null,"abstract":"Background: MedsCheck Annual (MCA) is an Ontario government-funded medication review service for individuals taking 3 or more prescription medications for chronic conditions. Methods: This cohort study analyzed linked administrative claims data from April 1, 2007, to March 31, 2013. Trends in MCA claims and recipient characteristics were examined. Results: A total of 1,498,440 Ontarians (55% seniors, 55% female) received an MCA. One-third (36%) had 2 or more MCAs within 6 years. Service provision increased over time, with a sharper increase from 2010 onward. Almost half of Ontario pharmacies made at least 1 MCA claim in the first month of the program. Hypertension, respiratory disease, diabetes, psychiatric conditions and arthritis were common comorbidities. Recipients older than 65 years were most commonly dispensed an antihypertensive and/or antihyperlipidemic drug in the prior year and received an average of 11 unique prescription medications. Thirty-eight percent of recipients visited an emergency department or were hospitalized in the year prior to their first MCA. Discussion: Over the first 6 years of the program, approximately 1 in 9 Ontarians received an MCA. There was rapid and widespread uptake of the service. Common chronic conditions were well represented among MCA recipients. Older MCA recipients had less emergency department use compared with population-based estimates. Conclusions: Medication reviews increased over time; however, the number of persons receiving the service more than once was low. Service delivery was generally consistent with program eligibility; however, there are some findings possibly consistent with delivery to less complex patients.","PeriodicalId":46612,"journal":{"name":"Canadian Pharmacists Journal","volume":"149 1","pages":"293 - 302"},"PeriodicalIF":1.5,"publicationDate":"2016-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1715163516662670","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65466717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 44

Pharmacy practice research produces findings that inform how pharmacists contribute to optimal drug therapy outcomes for Canadians 药学实践研究产生的发现，告知药剂师如何为加拿大人的最佳药物治疗结果做出贡献

IF 1.5

Canadian Pharmacists Journal Pub Date : 2016-08-08 DOI: 10.1177/1715163516663693

L. Dolovich, R. Tsuyuki

引用次数: 5

Pharmacists without Borders Canada 加拿大无国界药剂师组织

IF 1.5

Canadian Pharmacists Journal Pub Date : 2016-08-02 DOI: 10.1177/1715163516662816

S. Levesque

引用次数: 1

The community pharmacist’s role in cancer screening and prevention 社区药剂师在癌症筛查和预防中的作用

IF 1.5

Canadian Pharmacists Journal Pub Date : 2016-07-29 DOI: 10.1177/1715163516660574

Anthony James Havlicek, H. Mansell

引用次数: 10

Inhaler assessment in COPD patients COPD患者吸入器评估

IF 1.5

Canadian Pharmacists Journal Pub Date : 2016-07-27 DOI: 10.1177/1715163516660573

Shelby Dougall, J. Bolt, W. Semchuk, Tanya Winkel

引用次数: 12